Poseida focuses on progressing cell and gene therapies that have the potential to cure cancers and rare diseases. Credit: ...

From Merck & Co to Sanofi, Pharmaceutical Technology lists the leading pharmaceutical companies spending the most on R&D in ...

Pfizer’s reported net income stood at $3.11bn in Q1 2024, marking a decrease of 44% from $5.54bn posted in the same period of ...

The FDA approval allows Boehringer Ingelheim’s Cyltezo to be used as an interchangeable biosimilar to Humira. Credit: Tada ...

Janssen-Cilag has sought expanded European Medicines Agency (EMA) approval for TREMFYA to treat active ulcerative colitis and Crohn’s disease.

The updated identity is part of international sweeping changes by J&J as the big pharma unites its medtech and pharmaceutical ...

Following the RSV therapy and vaccine rollout, understanding molecular glues, using pharmacovigilance for active drug ...

The sprinkle formulation of Ingrezza is approved as an alternative for Huntington’s patients who have difficulty swallowing.

The US-based company is working alongside the University of Texas MD Anderson Cancer Center to fund the Phase I/II clinical ...

Roche released promising first-quarter (Q1) 2024 sales figures for VABYSMO, a vascular endothelial growth factor (VEGF) and ...

AstraZeneca has maintained that while the vaccine may, in “very rare” cases, cause TTS, the casual mechanism for this effect remains unknown.

Novartis and Japanese biopharmaceutical company PeptiDream have expanded their partnership for the discovery of peptides.